Skip to main content
Equibles

4512 · WAKAMOTO PHARMACEUTICAL CO.,LTD. · Financials

Use 4512 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4512.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
287 JPY -1 (-0.35%) At close · Nov 13
Rebalance outlook locked
Market Cap
9.96B JPY
Shares
34.71M
Volume · Nov 13 6900 Avg daily vol (3M) 39.28K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
9.91B +27.2%
FY2026 Revenue FY2022–FY2026
Net Income
227.22M +252.6%
FY2026 Net Income FY2022–FY2026
Gross Margin
47.75% +1.2pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
2.58% +8.5pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
-486.91M +17.8%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 9.91B 7.79B 7.74B 8.66B 8.38B
JPY 5.18B 4.17B 4.14B 4.55B 4.03B
JPY 4.73B 3.62B 3.6B 4.11B 4.36B
JPY 255.54M -457.8M -195.51M 141.47M -13.39M
JPY 256.4M 7.46M 158.85M 211.57M 284.86M
JPY 29.18M -56.98M 49.9M 73.32M 46.31M
JPY 227.22M 64.44M 108.96M 138.26M 238.54M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 312.2M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.